Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Karla Mayfield, Dan Siskind, Karl Winckel, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 3, pp. 227-236
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Joseph Firth, Najma Siddiqi, Ai Koyanagi, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 8, pp. 675-712
Open Access | Times Cited: 1134
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
Julie Rask Larsen, Louise Vedtofte, Mathilde S. L. Jakobsen, et al.
JAMA Psychiatry (2017) Vol. 74, Iss. 7, pp. 719-719
Open Access | Times Cited: 179
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 238-238
Open Access | Times Cited: 158
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
Dan Siskind, Janni Leung, Anthony Russell, et al.
PLoS ONE (2016) Vol. 11, Iss. 6, pp. e0156208-e0156208
Open Access | Times Cited: 104
Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
Dan Siskind, Margaret Hahn, Christoph U. Correll, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 2, pp. 293-302
Closed Access | Times Cited: 101
Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis
Ronald J. Gurrera, Priya Gearin, Jonathan Love, et al.
Acta Psychiatrica Scandinavica (2022) Vol. 145, Iss. 5, pp. 423-441
Closed Access | Times Cited: 39
Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 38
Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX)
Dan Siskind, Anthony Russell, Clare Gamble, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 4, pp. 1050-1055
Closed Access | Times Cited: 69
A Focused Review of the Metabolic Side-Effects of Clozapine
Jessica W. Y. Yuen, David D. Kim, Ric M. Procyshyn, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 53
Understanding the Effects of Antipsychotics on Appetite Control
Sayani Mukherjee, Silje Skrede, Edward Milbank, et al.
Frontiers in Nutrition (2022) Vol. 8
Open Access | Times Cited: 35
Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia
Wade Marteene, Karl Winckel, Samantha Hollingworth, et al.
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 12, pp. 1149-1160
Open Access | Times Cited: 47
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 5
The Impact of Metformin on Weight and Waist Circumference in Patients Treated With Clozapine: A One‐Year Retrospective Cohort Study
Bee Leng Per, Susan Loeser, Suzanne Edwards, et al.
Acta Psychiatrica Scandinavica (2025)
Open Access
One‐year follow‐up on liraglutide treatment for prediabetes and overweight/obesity in clozapine‐ or olanzapine‐treated patients
Camilla Kara Svensson, Julie Rask Larsen, Louise Vedtofte, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 139, Iss. 1, pp. 26-36
Open Access | Times Cited: 43
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Longqing Zhang, Wen Zhang, Xuebi Tian
International Journal of Neuroscience (2021) Vol. 133, Iss. 5, pp. 473-491
Closed Access | Times Cited: 27
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
Approaches to mitigate weight gain associated with antipsychotic use
Florian Tran, Allan J. Barnes, Rebecca Urbonas, et al.
Personalized Medicine in Psychiatry (2025) Vol. 51-52, pp. 100151-100151
Closed Access
Immune and metabolic alterations in first episode psychosis (FEP) patients
Luisella Bocchio‐Chiavetto, Roberta Zanardini, Sarah Tosato, et al.
Brain Behavior and Immunity (2018) Vol. 70, pp. 315-324
Closed Access | Times Cited: 37
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?
Svetlina Vasileva, J. Tucker, Dan Siskind, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 5, pp. 625-639
Closed Access | Times Cited: 16
High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine
Julie Rask Larsen, Camilla Kara Svensson, Louise Vedtofte, et al.
CNS Spectrums (2018) Vol. 24, Iss. 4, pp. 441-452
Closed Access | Times Cited: 24
Metabolic monitoring and management among clozapine users
Grace Tso, Puja Kumar, T. M. D. U. Jayasooriya, et al.
Australasian Psychiatry (2016) Vol. 25, Iss. 1, pp. 48-52
Closed Access | Times Cited: 23
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
Dan Siskind, Nadia Friend, Anthony Russell, et al.
BMJ Open (2018) Vol. 8, Iss. 3, pp. e021000-e021000
Open Access | Times Cited: 19
Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis
Abdulrhman Khaity, Nada Mostafa Al-dardery, Khaled Albakri, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches
Hesham Shamshoum, Kyle D. Medak, David C. Wright
Behavioural Brain Research (2020) Vol. 400, pp. 113049-113049
Closed Access | Times Cited: 15
Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)
Dan Siskind, Andrea Baker, Anthony Russell, et al.
BJPsych Open (2023) Vol. 9, Iss. 4
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top